Immunic (IMUX) vs Kazia Therapeutics (KZIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Kazia Therapeutics (KZIA) has outperformed Immunic (IMUX) over the past year, gaining 23.2% versus a loss of 15.8%. Over five years, IMUX leads with a -91.3% price change compared with -98.3% for KZIA. Immunic is the larger company by market cap ($111.7 million vs $102.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | KZIA |
|---|---|---|
| Share price | $8.19 | $8.93 |
| Market cap | $111.75M | $102.04M |
| 1-day change | +8.33% | +1.25% |
| YTD return | +41.57% | +28.01% |
| 1-year return | -15.81% | +23.18% |
| 5-year return | -91.28% | -98.30% |
| EPS (TTM) | $-3.83 | $-6.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.43 | $17.40 |
| 52-week low | $5.06 | $4.86 |
| Distance from 52-week high | -53.01% | -48.68% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +426.13% | +216.46% |
| Average volume | 284.68K | 262.41K |
| Shares outstanding | 13.64M | 11.43M |
| Employees | 100 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KZIA has outperformed IMUX by 39.0 percentage points over the past year.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Kazia Therapeutics
KZIA stock →Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
IMUX vs KZIA FAQ
Which is bigger, Immunic or Kazia Therapeutics?
Immunic (IMUX) is larger, with a market capitalization of $111.75M compared with $102.04M for Kazia Therapeutics (KZIA).
Which stock has performed better over the past year, IMUX or KZIA?
KZIA returned +23.18% over the past 12 months, compared with -15.81% for IMUX (price return, excluding dividends). Past performance does not predict future results.
Are Immunic and Kazia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.